Pasithea Therapeutics Corp. (KTTA): Nasdaq/NYSE listing notice — Pasithea receives Nasdaq bid price deficiency notice; 180-day cure period

Pasithea Therapeutics Corp.

Received Nasdaq notice on Feb 20, 2026 for failing minimum $1.00 bid price for 30 consecutive business days.
Company has until August 19, 2026 to regain compliance; needs closing bid >=$1.00 for 10 consecutive days.
If not cured, may qualify for additional 180 days if it meets other listing standards and considers reverse split.
Notice does not affect business operations or SEC reporting; company evaluating options to regain compliance.

item 3.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.9

Pasithea Therapeutics Corp. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).

Exchange: nasdaq
Notice: deficiency notice
Deficiency: minimum bid price
Rules: 5550(a)(2)

Exact text from the filing

February 20, 2026, Pasithea Therapeutics Corp. (the “Company”) received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company is not in compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market (the “Bid Price Requirement”). The Notice does not result in the immediate delisting of the Company’s common stock from The Nasdaq Capital Market. The Nasdaq Listing Rules require listed securities to maintain a minimum bid pr

View on SEC.gov

5 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

Pasithea Therapeutics Corp. filing history →

Source: SEC EDGAR

accession 0001213900-26-018874

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.